Table 1.
Activation of mTORC1 signaling in human cancers
| Cancer | p4E-BP1 | pS6K (T389) | pS6 | pmTOR (S2448)* | N | References |
|---|---|---|---|---|---|---|
| Breast | 71.9% | 58.5% (S235/236) | 44.9% | 89 | (Lin et al., 2005) | |
| 41.2% (S65) | 42.4% | 165 | (Zhou et al., 2004) | |||
| 87.3% (T70) | 77.7% | 77.7% (S240/244) | 103 | (Rojo et al., 2007) | ||
| Colorectal | 82.1% (T37/46) | 66.1% | 60.7% | 56 | (Zhang et al., 2009) | |
| 40% | 69 | (Nozawa et al., 2007) | ||||
| Endometrial | 61% (S235/236) | 75 | (Lu et al., 2008) | |||
| Glioblastoma | 56% | 56 | (Chakravarti et al., 2004) | |||
| 94% | 75% | 268 | (Pelloski et al., 2006) | |||
| Hepatocellular Carcinoma | 47.7% (S240/244) | 86 | (Villanueva et al., 2008) | |||
| 88.3% (S235/236) | 528 | (Zhou et al., 2009) | ||||
| Lung Adenocarcinoma | 84% (S235/236) | 77 | (McDonald et al., 2008) | |||
| 100% 54% high (S235/236) |
37 | (Conde et al., 2006) | ||||
| Lymphoma | 66% (T70) | 66% | 66% (S240/244) | 66% | 29 | (Vega et al., 2006) |
| Melanoma | 73% (S235/236) | 107 | (Karbowniczek et al., 2008) | |||
| Ovarian | 41.1% (T70) | 26.4% | 15.5% (S240/244) | 129 | (Castellvi et al., 2006) | |
| Prostate | 90.6% (T70) | 71.7% (S235/236) | 96.2% | 84 | (Kremer et al., 2006) | |
| Renal Cell Carcinoma | 59% (S235/236) | 29 | (Robb et al., 2007) | |||
| 85% (S235/236) | 375 | (Pantuck et al., 2007) |
*
Studies using P-mTOR (S2448) alone were not included, as the functional relevance of this site is unknown.